{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T17:08:46Z","timestamp":1745946526188,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Parasit Dis"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12639-021-01379-w","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T09:02:34Z","timestamp":1616490154000},"page":"903-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of single-dose liposomal amphotericin B in patients with visceral leishmaniasis in Bangladesh: a real-life experience"],"prefix":"10.1007","volume":"45","author":[{"given":"Md. Rezaul","family":"Ekram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Robed","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-1739","authenticated-orcid":false,"given":"Mohammad Jahid","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Abdullah Saeed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajib","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranab Kumar","family":"Mallik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Lister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monjur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"3","key":"1379_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40475-014-0027-6","volume":"1","author":"BN Ahmed","year":"2014","unstructured":"Ahmed BN, Nabi SG, Rahman M, Selim S, Bashar A, Rashid MM, Lira FY, Choudhury TH, Mondal D (2014) Kala-azar (Visceral Leishmaniasis) elimination in Bangladesh: successes and challenges. Curr Trop Med Rep 1(3):163\u2013169. https:\/\/doi.org\/10.1007\/s40475-014-0027-6","journal-title":"Curr Trop Med Rep"},{"issue":"5","key":"1379_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"R Arenas","year":"2017","unstructured":"Arenas R, Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J (2017) Leishmaniasis: a review. F1000Research 6(5):1\u201315. https:\/\/doi.org\/10.12688\/f1000research.11120.1","journal-title":"F1000Research"},{"issue":"4","key":"1379_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14728214.2012.748036","volume":"17","author":"M Balasegaram","year":"2012","unstructured":"Balasegaram M, Ritmeijer K, Lima MA, Burza S, Genovese GO, Milani B, Gaspani Y, Potet J, Chappuis C (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17(4):493\u2013510. https:\/\/doi.org\/10.1517\/14728214.2012.748036","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"1379_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3201\/eid1105.040718","volume":"11","author":"C Bern","year":"2005","unstructured":"Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, Wagatsuma Y, Haque R, Kurkjian K, Vaz EL, Begum M, Akter T, Cetre-Sossah CB, Ahluwalia IB, Dotson E, Secor WE, Breiman RF, Maguire JH (2005) Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 11(5):655\u2013662. https:\/\/doi.org\/10.3201\/eid1105.040718","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"1379_CR5","first-page":"275","volume":"123","author":"C Bern","year":"2006","unstructured":"Bern C, Chowdhury R (2006) The epidemiology of visceral leishmaniasis in Bangladesh: Prospects for improved control. Indian J Med Res 123(3):275\u2013288","journal-title":"Indian J Med Res"},{"issue":"1","key":"1379_CR6","doi-asserted-by":"publisher","first-page":"e2536","DOI":"10.1371\/journal.pntd.0002536","volume":"8","author":"S Burza","year":"2014","unstructured":"Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balasegaram M, Das P (2014) Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis 8(1):e2536. https:\/\/doi.org\/10.1371\/journal.pntd.0002536","journal-title":"PLoS Negl Trop Dis"},{"issue":"10151","key":"1379_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S01406736(18)31204-3","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392(10151):951\u2013970. https:\/\/doi.org\/10.1016\/S01406736(18)31204-3","journal-title":"Lancet"},{"issue":"2","key":"1379_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1515\/jtim-2015-0002","volume":"3","author":"SP Georgiadou","year":"2015","unstructured":"Georgiadou SP, Makaritsis KP, Dalekos GN (2015) Leishmaniasis revisited: current aspects on epidemiology, diagnosis and treatment. J Transl Intern Med 3(2):43\u201350","journal-title":"J Transl Intern Med"},{"key":"1379_CR500","unstructured":"Ghalib CM (2014) Update on the Kala-Azar elimination program in Bangladesh. Health  Sci Bullet 12(4):7\u201313"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/s0025727300042691","volume":"27","author":"M Gibson","year":"1983","unstructured":"Gibson M (1983) The identification of kala-azar and the discovery of Leishmania Donovani. Med Hist 27:203\u2013213. https:\/\/doi.org\/10.1017\/s0025727300042691","journal-title":"Med Hist"},{"issue":"1","key":"1379_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-018-4036-8","volume":"11","author":"MG Hasnain","year":"2018","unstructured":"Hasnain MG, Nath P, Maruf S, Nabi SG, Hossain AFMA, Ahmed BN, Mondal D, Basher A (2018) Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study. BMC Res Notes 11(1):1\u20135. https:\/\/doi.org\/10.1186\/s13104-018-4036-8","journal-title":"BMC Res Notes"},{"key":"1379_CR11","unstructured":"Health Bulletin 2018. Government of the People's Republic of Bangladesh, Ministry of the Health and Family welfare"},{"issue":"7","key":"1379_CR12","doi-asserted-by":"publisher","first-page":"e005408","DOI":"10.1136\/bmjopen-2014-005408","volume":"4","author":"MM Huda","year":"2014","unstructured":"Huda MM, Chowdhury R, Ghosh D, Dash AP, Bhattacharya SK, Mondal D (2014) Visceral leishmaniasis-associated mortality in Bangladesh: a retrospective cross-sectional study. BMJ Open 4(7):e005408. https:\/\/doi.org\/10.1136\/bmjopen-2014-005408","journal-title":"BMJ Open"},{"key":"1379_CR13","unstructured":"Kala-azar program 2020, DHis2 online database, People's Republic of Bangladesh: Bangladesh National Portal"},{"key":"1379_CR14","unstructured":"KalaCORE: control and elimination of visceral leishmaniasis, Bangladesh 2020. http:\/\/www.kalacore.org\/. Acccesed 17 Aug 2020"},{"issue":"4","key":"1379_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0003699","volume":"9","author":"E Lucero","year":"2015","unstructured":"Lucero E, Collin SM, Gomes S, Akter F, Asad A, Das AK, Ritmeijer K (2015) Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis 9(4):1\u201311. https:\/\/doi.org\/10.1371\/journal.pntd.0003699","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1379_CR16","first-page":"267","volume":"123","author":"N Malla","year":"2006","unstructured":"Malla N, Mahajan RC (2006) Pathophysiology of visceral leishmaniasis\u2014some recent concepts. Indian J Med Res 123(3):267\u2013274","journal-title":"Indian J Med Res"},{"issue":"1","key":"1379_CR17","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2214-109X(13)70118-9","volume":"2","author":"D Mondal","year":"2014","unstructured":"Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B (2014) Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Heal 2(1):e51\u2013e57. https:\/\/doi.org\/10.1016\/S2214-109X(13)70118-9","journal-title":"Lancet Glob Heal"},{"key":"1379_CR18","unstructured":"National Guideline for Kala-azar Case Management (2013) Kala-azar Elimination Program Communicable Disease Control (CDC) and Directorate General of Health Services, Ministry of Health and Family Welfare Government of the People\u2019s Republic of Bangladesh. https:\/\/www.who.int\/leishmaniasis\/burden\/National_Guideline_for_Kala-azar_Case_Management_Bangladesh_2013.pdf?ua=1"},{"issue":"2","key":"1379_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjd.15119","volume":"177","author":"K Pandey","year":"2017","unstructured":"Pandey K, Pal B, Das BNR, Murti K, Lal CS, Verma N, Bimal S, Ali V, Verma RB, Topno RK, Siddiqi NA, Das P (2017) Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. Br J Dermatol 177(2):557\u2013559. https:\/\/doi.org\/10.1111\/bjd.15119","journal-title":"Br J Dermatol"},{"key":"1379_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5224","author":"S Rijal","year":"2019","unstructured":"Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M (2019) Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ. https:\/\/doi.org\/10.1136\/bmj.k5224","journal-title":"BMJ"},{"issue":"2","key":"1379_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4269\/ajtmh.2010.10-0156","volume":"83","author":"PK Sinha","year":"2010","unstructured":"Sinha PK, Roddy P, Palma PP, Kociejowski A, Mar\u00eda Lima AN, Das VNR, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, SeenaS BM, Parre\u00f1o F, Pandey K (2010) Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83(2):357\u2013364. https:\/\/doi.org\/10.4269\/ajtmh.2010.10-0156","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"1379_CR23","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/S2214-109X(13)70141-7","volume":"2","author":"PK Sinha","year":"2014","unstructured":"Sinha PK, Bhattacharya S (2014) Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis. Lancet Glob Heal 2(1):e7. https:\/\/doi.org\/10.1016\/S2214-109X(13)70141-7","journal-title":"Lancet Glob Heal"},{"issue":"2","key":"1379_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.icb7100011","volume":"85","author":"AC Stanley","year":"2007","unstructured":"Stanley AC, Engwerda CR (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85(2):138\u2013147. https:\/\/doi.org\/10.1038\/sj.icb7100011","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"1379_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/cid\/cis474","volume":"55","author":"S Sundar","year":"2012","unstructured":"Sundar S, Singh A, Rai M, Prajapati KV, Singh AK, Ostyn B, Boelaert M, Dujardin Chakravarty J (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis Off Publ Infect Dis Soc Am 55(4):543\u2013550. https:\/\/doi.org\/10.1093\/cid\/cis474","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"6","key":"1379_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362(6):504\u2013512. https:\/\/doi.org\/10.1056\/NEJMoa0903627","journal-title":"N Engl J Med"},{"issue":"2","key":"1379_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777X.62886","volume":"2","author":"S Sundar","year":"2010","unstructured":"Sundar S, Jaya J (2010) Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis 2(2):159. https:\/\/doi.org\/10.4103\/0974-777X.62886","journal-title":"J Glob Infect Dis"},{"issue":"3","key":"1379_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/380971","volume":"38","author":"S Sundar","year":"2004","unstructured":"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis Off Publ Infect Dis Soc Am 38(3):377\u2013383. https:\/\/doi.org\/10.1086\/380971","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"1379_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1746-1","volume":"16","author":"A Tamiru","year":"2016","unstructured":"Tamiru A, Tigabu B, Yifru S, Diro E, Hailu A (2016) Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. BMC Infect Dis 16(1):1\u20137. https:\/\/doi.org\/10.1186\/s12879-016-1746-1","journal-title":"BMC Infect Dis"},{"issue":"6","key":"1379_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"E Torres-guerrero","year":"2017","unstructured":"Torres-guerrero E, Quintanilla-cedillo MR, Ruiz-esmenjaud J, Arenas R (2017) Leishmaniasis: a review. F1000Research 6(6):1\u201315. https:\/\/doi.org\/10.12688\/f1000research.11120.1","journal-title":"F1000Research"},{"issue":"5","key":"1379_CR32","first-page":"605","volume":"33","author":"B Veress","year":"1977","unstructured":"Veress B, Omer A, Satir AA, El Hassan AM (1977) Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 33(5):605\u2013610","journal-title":"Immunology"},{"key":"1379_CR33","first-page":"22","volume":"949","author":"World Health Organization","year":"2010","unstructured":"World Health Organization (2010) Control of the leishmaniases. World Health Organ Tech Rep Ser 949:22\u201326","journal-title":"World Health Organ Tech Rep Ser"},{"key":"1379_CR34","unstructured":"World Health Organization (WHO) (2017). Leishmaniasis country profiles. WHO"},{"issue":"2","key":"1379_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.24171\/j.phrp.2018.9.2.07","volume":"9","author":"N Zahra","year":"2018","unstructured":"Zahra N, Davood K, Morteza A, Zahra S (2018) Epidemiological aspects of visceral leishmaniasis in Larestan and Ghiro-Karzin Counties, Southwest of Iran. Osong Public Heal Res Perspect 9(2):81\u201385. https:\/\/doi.org\/10.24171\/j.phrp.2018.9.2.07","journal-title":"Osong Public Heal Res Perspect"}],"container-title":["Journal of Parasitic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12639-021-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12639-021-01379-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12639-021-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T17:37:43Z","timestamp":1635529063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12639-021-01379-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s12639-021-01379-w","relation":{},"ISSN":["0971-7196","0975-0703"],"issn-type":[{"type":"print","value":"0971-7196"},{"type":"electronic","value":"0975-0703"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"21 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interests regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical review committee of Dhaka Medical College Hospital <i>(Memo no. MEU-DMC\/ECC\/2016\/53-D)<\/i> and the study conformed to the current Declaration of Helsinki. Moreover, confidentiality and anonymity were maintained in all over the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The researcher was duly concerned about the ethical issues related to the study. Formal ethical clearance was taken from the Ethical Review Committee (ERC) of the DMC for conducting the study as well as formal permission was taken from the responders. Confidentiality was maintained properly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical consideration"}},{"value":"Informed written consent was taken from the subject informing the nature & purpose of the study, the procedure of the study, the right to refuse, accept & withdraw to participate in the study as well as the participants didn't gain financial benefit from this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}